Case Studies

Overview

Attomarker, a pioneer in nanoparticle plasmon technology, partnered with Psephos Biomedica to bring its Liscar6 platform to market for COVID-19 testing. Originally developed for broader diagnostic applications, the technology was rapidly repurposed during the pandemic to support urgent public health needs.

The Challenge

As the COVID-19 pandemic emerged, Attomarker needed to quickly pivot its technology to deliver reliable diagnostic solutions. This required:

• Securing MHRA emergency use exemption

• Achieving CE marking for its IVD device

• Developing robust technical documentation and performance evaluation

• Establishing a compliant Quality Management System (QMS)

• Accelerating timelines without compromising regulatory standards

• The Solution